Axi-cel治疗大B细胞淋巴瘤后的免疫重建与感染并发症
单中心研究评估41例接受axi-cel治疗的复发难治大B细胞淋巴瘤患者的长期血液学恢复、免疫重建及感染并发症。3级以上血细胞减少见于97.6%患者,但多数6个月内恢复;1年时仅40%患者CD19+ B细胞可检测,18个月时50%患者CD4+ T细胞低于200/μL。感染在前28天显著更多且多为轻中度,使用糖皮质激素是唯一感染预测因素(HR 3.69)。
要点
- axi-cel后3级以上血细胞减少发生率97.6%,多数6个月内恢复。
- 1年时仅40%患者CD19+ B细胞恢复,免疫重建延迟常见。
- 使用糖皮质激素是感染的唯一独立预测因素。
核心结论
- axi-cel治疗后免疫重建延迟可持续至18个月,感染风险与糖皮质激素使用相关。
- 结果支持在axi-cel后12个月以上仍进行长期监测和抗微生物预防。
研究设计与样本
- 单中心研究,纳入41例接受axicabtagene ciloleucel治疗的复发或难治性大B细胞淋巴瘤患者。
- 评估输注后长期血液学恢复、免疫重建和感染并发症。
主要发现
- 输注后28天内3级以上血细胞减少发生率为97.6%,多数在6个月内缓解。
- 63.4%患者接受红细胞输注,34.1%接受血小板输注,36.6%接受静脉免疫球蛋白,51.2%在28天后接受粒细胞集落刺激因子注射。
- 1年时仅40%患者可检测到CD19+ B细胞,18个月时50%患者CD4+ T细胞计数低于200个/μL。
- 持续缓解患者的B细胞发育不全持续时间显著更长,且与CD4+ T细胞计数恢复强相关。
- 前28天感染显著多于其他随访期,大多为轻中度;多因素分析中糖皮质激素使用是唯一感染预测因素(HR 3.69,95%CI 1.18-16.5)。
临床怎么用
- axi-cel后应进行超过12个月的长期监测和抗微生物预防。
- 对使用糖皮质激素的患者应加强感染风险评估与预防。
局限性
- 单中心研究,样本量41例。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). We evaluated the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) at a single center. Grade 3+ cytopenias occurred in 97.6% of patients within the first 28 days postinfusion, with most resolved by 6 months. Overall, 63.4% of patients received a red blood cell transfusion, 34.1% of patients received a platelet transfusion, 36.6% of patients received IV immunoglobulin, and 51.2% of patients received growth factor (granulocyte colony-stimulating factor) injections beyond the first 28 days postinfusion. Only 40% of patients had recovered detectable CD19+ B cells by 1 year, and 50% of patients had a CD4+ T-cell count <200 cells per μL by 18 months postinfusion. Patients with durable responses to axi-cel had significantly longer durations of B-cell aplasia, and this duration correlated strongly with the recovery of CD4+ T-cell counts. There were significantly more infections within the first 28 days compared with any other period of follow-up, with the majority being mild-moderate in severity. Receipt of corticosteroids was the only factor that predicted risk of infection in a multivariate analysis (hazard ratio, 3.69; 95% confidence interval, 1.18-16.5). Opportunistic infections due to Pneumocystis jirovecii and varicella-zoster virus occurred up to 18 months postinfusion in patients who prematurely discontinued prophylaxis. These results support the use of comprehensive supportive care, including long-term monitoring and antimicrobial prophylaxis, beyond 12 months after axi-cel treatment.
引用
- Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Adv. 2021. PMID: 33570626. doi:10.1182/bloodadvances.2020002732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。